{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:27Z","timestamp":1792239087652,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00411768"],"award-info":[{"award-number":["RS-2024-00411768"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00465298"],"award-info":[{"award-number":["RS-2024-00465298"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-00542986"],"award-info":[{"award-number":["RS-2025-00542986"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00451880"],"award-info":[{"award-number":["RS-2024-00451880"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023-00261343"],"award-info":[{"award-number":["RS-2023-00261343"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-25455885"],"award-info":[{"award-number":["RS-2025-25455885"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jconrel.2025.114520","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:02:23Z","timestamp":1765148543000},"page":"114520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia"],"prefix":"10.1016","volume":"390","author":[{"given":"Miyoung","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjoo","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heechun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songseop","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonhyo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaesung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyukjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114520_bb0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd.2018.70","article-title":"Advances and innovations in haemophilia treatment","volume":"17","author":"Peters","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114520_bb0010","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2025.114520_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia a and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jconrel.2025.114520_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2025.114520_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.jconrel.2025.114520_bb0030","first-page":"1334","article-title":"Emicizumab: the hemophilia a game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2025.114520_bb0035","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMc2502741","article-title":"Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia a","volume":"392","author":"Zhang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114520_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.thromres.2020.12.033","article-title":"AAV mediated gene therapy for haemophilia B: from the early attempts to modern trials","volume":"236","author":"Muczynski","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jconrel.2025.114520_bb0045","first-page":"20","article-title":"New treatment available for hemophilia A or B","volume":"125","author":"Aschenbrenner","year":"2025","journal-title":"Am. J. Nurs."},{"key":"10.1016\/j.jconrel.2025.114520_bb0050","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1021\/acsptsci.4c00560","article-title":"Advances in development of drug treatment for hemophilia with inhibitors","volume":"7","author":"Wichaiyo","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2025.114520_bb0055","doi-asserted-by":"crossref","first-page":"eabj6901","DOI":"10.1126\/sciadv.abj6901","article-title":"In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.114520_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2025.114520_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14092961","article-title":"Concizumab, a non-replacement therapy for persons with hemophilia with inhibitors","volume":"14","author":"Castaman","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.114520_bb0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2025.114520_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120164","article-title":"From cell line development to the formulated drug product: the art of manufacturing therapeutic monoclonal antibodies","volume":"594","author":"Carrara","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114520_bb0080","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s00253-016-7388-9","article-title":"Advances in recombinant antibody manufacturing","volume":"100","author":"Kunert","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114520_bb0085","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4161\/mabs.2.5.12720","article-title":"Cell culture processes for monoclonal antibody production","volume":"2","author":"Li","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2025.114520_bb0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/07853890802698842","article-title":"Challenges in monoclonal antibody-based therapies","volume":"41","author":"Samaranayake","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.jconrel.2025.114520_bb0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2013progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.jconrel.2025.114520_bb0100","article-title":"Advances and challenges in therapeutic monoclonal antibodies drug development, Brazilian","volume":"54","author":"Santos","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114520_bb0105","doi-asserted-by":"crossref","first-page":"eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2025.114520_bb0110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA delivery for therapeutic anti-HER2 antibody expression in vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114520_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In vivo delivery of nucleic acid-encoded monoclonal antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2025.114520_bb0120","article-title":"Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1","volume":"11","author":"Narayanan","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jconrel.2025.114520_bb0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7150\/jca.63991","article-title":"Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer","volume":"13","author":"Wu","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114520_bb0130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/rth2.12438","article-title":"MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia","volume":"4","author":"Kwak","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2025.114520_bb0135","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/jth.15244","article-title":"Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics","volume":"19","author":"Kwak","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2025.114520_bb0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nprot.2013.019","article-title":"Reprogramming human fibroblasts to pluripotency using modified mRNA","volume":"8","author":"Mandal","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.114520_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11033-019-05153-3","article-title":"Effects of different 2A peptides on transgene expression mediated by tricistronic vectors in transfected CHO cells","volume":"47","author":"Li","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jconrel.2025.114520_bb0150","doi-asserted-by":"crossref","first-page":"fcae100","DOI":"10.1093\/braincomms\/fcae100","article-title":"Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau","volume":"6","author":"Wongsodirdjo","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.jconrel.2025.114520_bb0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114520_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biom13111677","article-title":"Effects of combinations of untranslated-region sequences on translation of mRNA","volume":"13","author":"Kirshina","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2025.114520_bb0165","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.omtn.2021.10.007","article-title":"Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA","volume":"26","author":"Linares-Fernandez","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.114520_bb0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","article-title":"Effects of chemically modified messenger RNA on protein expression","volume":"27","author":"Li","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.114520_bb0175","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.114520_bb0180","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.omtn.2022.01.004","article-title":"Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages","volume":"27","author":"Moradian","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.114520_bb0185","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2alpha-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.114520_bb0190","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1093\/nar\/gkab1241","article-title":"Membrane-dependent relief of translation elongation arrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs","volume":"50","author":"Svitkin","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.114520_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10622","article-title":"Deconvolution of synthetic mRNA expression: nucleoside chemistry alters translatability","volume":"9","author":"Moradian","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114520_bb0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2021.11.022","article-title":"Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery","volume":"341","author":"Melamed","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114520_bb0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-1-0716-1374-0_20","article-title":"Effects of mRNA modifications on translation: an overview","volume":"2298","author":"Roy","year":"2021","journal-title":"Methods Mol. Biol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:23:56Z","timestamp":1781702636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925011344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S0168365925011344"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114520","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114520"}}